Real-world treatment outcome of advanced Chinese NSCLC EGFR exon 20 insertion patients.

被引：1
|
作者：
Wang, Yan
Yang, Guangjian
Li, Jun
Xu, Haiyan
Yang, Lu
Xu, Fei
Yang, Yaning
Xia, Bing
Zhu, Viola Weijia
Qiu, Weini
Ou, Sai-Hong Ignatius
机构：
[1] Chinese Acad Med Sci, Beijing Key Lab Clin Study Anticanc Mol Targeted, Dept Med Oncol, Natl Canc Ctr,Canc Hosp, Beijing, Peoples R China
[2] Peking Union Med Coll, Beijing, Peoples R China
[3] Chinese Acad Med Sci, Dept Med Oncol, Natl Clin Res Ctr Canc, Natl Canc Ctr,Canc Hosp, Beijing, Peoples R China
[4] Chinese Peoples Liberat Army Gen Hosp, Ctr Clin Lab Med, Beijing, Peoples R China
[5] Chinese Acad Med Sci, Natl Clin Res Ctr Canc, Dept Comprehens Oncol, Natl Canc Ctr,Canc Hosp, Beijing, Peoples R China
[6] USC Norris Cance Ctr, Los Angeles, CA USA
[7] Univ Calif Irvine, Chao Family Comprehens Canc Ctr, Sch Med, Orange, CA 92668 USA
[8] Healthy, Beijing, Peoples R China
[9] Univ Calif, Chao Family Comprehens Canc Ctr, Orange, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9043
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Comparative clinical outcomes for patients with advanced NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations
    Bazhenova, Lyudmila
    Minchom, Anna
    Viteri, Santiago
    Bauml, Joshua M.
    Ou, Sai-Hong Ignatius
    Gadgeel, Shirish M.
    Manuel Trigo, Jose
    Backenroth, Daniel
    Li, Tracy
    Londhe, Anil
    Mahadevia, Parthiv
    Girard, Nicolas
    LUNG CANCER, 2021, 162 : 154 - 161
  • [22] Amivantamab vs Real World Therapies for Advanced NSCLC with EGFR Exon20ins in China
    Shen, L.
    Hu, G.
    Wang, Y.
    Zhao, J.
    Li, X.
    Zhuo, J.
    Low, G.
    Lu, S.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S347 - S348
  • [23] Real-world EGFR testing in patients with advanced EGFRm NSCLC in Belgium (REVEAL)
    Cuppens, K.
    Lodewyckx, L.
    Demedts, I.
    Decoster, L.
    Colinet, B.
    Deschepper, K.
    Janssens, A.
    Pauwels, P.
    Galdermans, D.
    Pieters, T.
    ANNALS OF ONCOLOGY, 2020, 31 : S1117 - S1117
  • [24] Molecular characteristics of EGFR exon20 mutations in NSCLC patients.
    Ji, Yinghua
    Wang, Jin
    Meng, Xiangli
    Xie, Jinling
    Lu, Ping
    Li, Mengmeng
    Luo, Ningning
    Qi, Yingxue
    Zhu, Xiaofeng
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [25] Real-world EGFR testing patterns among US patients with advanced NSCLC
    Vanderpoel, Julie
    Pericone, Chris
    He, Jinghua
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (28)
  • [26] Amivantamab compared with real-world therapies in patients with NSCLC with EGFR Exon 20 insertion mutations who have progressed after platinum doublet chemotherapy.
    Minchom, Anna Rachel
    Girard, Nicolas
    Bazhenova, Lyudmila
    Ou, Sai-Hong Ignatius
    Gadgeel, Shirish M.
    Trigo, Jose
    Viteri, Santiago
    Backenroth, Daniel
    Bhattacharya, Archan
    Li, Tracy
    Mahadevia, Parthiv
    Bauml, Joshua
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [27] Real-world efficacy and safety of mobocertinib in EGFR exon 20 insertion-mutated lung cancer
    Kian, Waleed
    Christopoulos, Petros
    Remilah, Areen A.
    Levison, Esther
    Dudnik, Elizabeth
    Shalata, Walid
    Krayim, Bilal
    Marei, Ranin
    Yakobson, Alexander
    Faehling, Martin
    Kahala, Dolev
    Sara Granot, Inbal
    Levitas, Dina
    Peled, Nir
    Roisman, Laila C.
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [28] EGFR EXON 20 INSERTION MUTATIONS IN NSCLC: FREQUENCY AND TREATMENT OUTCOMES WITH EGFR DIRECTED TKIS
    Ovcaricek, T.
    Unk, M.
    Kern, I.
    Cufer, T.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (06) : S64 - S64
  • [29] Treatment comparison of amivantamab vs. real-world therapies among patients with NSCLC harboring EGFR Exon 20 insertion mutations: An external control analysis (ECA) using NTUH NSCLC dataset in Taiwan
    Wu, J-y.
    Zhuo, J.
    Chen, E.
    Wang, S-p.
    Hsieh, J-f.
    Shih, J-y.
    ANNALS OF ONCOLOGY, 2024, 35
  • [30] Afatinib in the treatment of advanced NSCLC with EGFR mutation: An observational real-world study.
    Li, Yun
    Wang, Xiaohua
    Wang, Li
    Kou, Yingying
    Ma, Xianglei
    Feng, Ji Feng
    Xiao, Mingzhe
    Shi, Meiqi
    Tang, Yiqun
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345